This makes up the rationale for cisplatin treatment in DLBCL, where an additional hampering of the DNA repair machinery using Hsp90 inhibitors could be beneficial when attempting to improve clinical outcome and overcome treatment resistance, especially in the most resistant patients. The gene discussed is HSP90AA1; the disease is diffuse large B-cell lymphoma.